Pharmabiz4d
US FDA grants fast track designation to Rznomics’ gene therapy-based cancer drug candidate, RZ-001
US FDA grants fast track designation to Rznomics’ gene therapy-based cancer drug candidate, RZ-001: Seongnam, South Korea Wednesday, February 19, 2025, 16:00 Hrs [IST] Rznomics, ...
Pharmaceutical Technology5d
FDA grants fast track status to Rznomics’ RZ-001 for HCC
The US FDA has granted fast track designation to Rznomics' RZ-001 for the treatment of hepatocellular carcinoma (HCC).